NCT03873987 - Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

July 16, 2019

Primary Completion Date

August 27, 2019

Study Completion Date

September 4, 2019

Conditions

Acute Bacterial Skin and Skin Structure Infection

Interventions

DRUG

Current Formulation of Oritavancin

Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)

DRUG

Kimyrsa

New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)

Trial Locations (4)

ML-ORI-102 Study Site, Burr Ridge

ML-ORI-102 Study Site, Chula Vista

ML-ORI-102 Study Site, La Mesa

ML-ORI-102 Study Site, Somers Point